S1314 correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): Implications for bladder preservation.

Authors

Elizabeth Plimack

Elizabeth R. Plimack

Fox Chase Cancer Center, Philadelphia, PA

Elizabeth R. Plimack , Catherine Tangen , Melissa Plets , Rutika Kokate , Joanne Xiu , Chadi Nabhan , Eric A. Ross , Erin Grundy , Woonyoung Choi , Colin P.N. Dinney , I-Ling C. Lee , Scott Lucia , Thomas W. Flaig , David James McConkey

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Urothelial Cancer - Local-Regional Disease

Clinical Trial Registration Number

NCT02177695

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4581)

DOI

10.1200/JCO.2022.40.16_suppl.4581

Abstract #

4581

Poster Bd #

72

Abstract Disclosures

Similar Posters

First Author: Benjamin Miron

First Author: Yongjune Lee

Poster

2018 Genitourinary Cancers Symposium

A phase II trial of risk-adapted treatment for muscle invasive bladder cancer after neoadjuvant accelerated MVAC.

A phase II trial of risk-adapted treatment for muscle invasive bladder cancer after neoadjuvant accelerated MVAC.

First Author: Daniel M. Geynisman

First Author: Srikala S. Sridhar